No quarterly revenue total was found in ENVERIC BIOSCIENCES, INC.'s SEC filings.
Enveric Biosciences, Inc. (ENVB) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-3.03M
-20.2% vs year-ago quarter
Operating cash flow
$-2.44M
-29.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.76
+93.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.48M
+37.9% vs year-ago quarter
Net cash
—
Operating margin
-0.1%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENVB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 890821
- Former names
- AMERI Holdings, Inc. (until Dec 30, 2020); SPATIALIZER AUDIO LABORATORIES INC (until May 27, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.0M | -$1.6M | -$2.2M | -$1.9M | -$2.5M |
| Net income | -$3.0M | -$1.6M | -$2.2M | -$1.9M | -$2.5M |
| Diluted EPS | -$0.76 | -$1.08 | -$6.17 | -$10.81 | -$11.65 |
| Operating cash flow | -$2.4M | -$2.3M | -$1.8M | -$2.1M | -$1.9M |
| Total assets | $8.9M | $5.5M | $5.1M | $4.4M | $3.5M |
| Stockholders' equity | $8.1M | $5.1M | $4.2M | $3.5M | $2.2M |
| Cash and investments | $8.3M | $4.9M | $4.7M | $3.8M | $2.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Jun 9, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 9, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 29, 2026 | May 22, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 1000 Enveric Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.